FDA Approves Oral Wegovy: A Game-Changer for Weight Loss and Food Trends? The FDA has approved Novo Nordisk's oral Wegovy—a once-daily pill with semaglutide—for weight management in adults with obesity or overweight plus related conditions. Launching in January 2026, it offers similar effectiveness to the injectable version (around 16-17% weight loss) but with greater convenience and potentially lower cost. This pill could overcome barriers like needle fear, boosting adoption among the millions

Novo's GLP-1 pill gets approved, Trump Media stock pulls back

Watch Dr Zahid Miyan explain how GLP‑1 therapies have revolutionised care beyond diabetes — including obesity, cardiovascular disease ❤️ and other chronic conditions — supported by robust clinical trial data 📊. Be wary of false or misleading claims on social media ⚠️; rely on authentic, verifiable sources ✅ . When in doubt, consult your healthcare professional to make an informed decision 🩺 #NovoNordiskPakistan #GLP1Facts #GetTheFactsRight | Novo Nordisk Pakistan